The 20x authorized share increase is a clear signal that the company plans significant equity issuance, likely for capital raises or M&A. With a $12M market cap and 1.5B authorized shares, the potential for extreme dilution is severe. Monitor for a follow-on offering filing (S-1 or prospectus supplement) in the coming weeks. The executive employment agreements are routine and do not change the bearish read from the authorized share expansion.
Price Chart
Executive Summary
BioRestorative Therapies filed an 8-K reporting the entry into new 3-year employment agreements with CEO Lance Alstodt (salary unchanged at $600,000) and CFO Robert Kristal (salary unchanged at $350,000), effective May 27, 2026. Separately, at a Special Meeting on May 26, 2026, stockholders approved a massive increase in authorized common shares from 75 million to 1.5 billion — a 20x expansion that creates massive dilution overhang for the $12M market cap company. The authorized share increase is the material event; the executive employment agreements are routine.
Key Facts
- Stockholders approved increasing authorized common shares from 75,000,000 to 1,500,000,000 — a 20x increase.
- Vote was 9,868,606 For, 2,389,059 Against, 179,207 Abstentions — passed with ~79% of votes cast in favor.
- CEO Lance Alstodt entered a 3-year employment agreement with $600,000 annual salary (unchanged).
- CFO Robert Kristal entered a 3-year employment agreement with $350,000 annual salary (unchanged).
- Both agreements include single-trigger change-in-control vesting of all equity awards and cash severance equal to 2x (Alstodt) or 1x (Kristal) salary plus max bonus.
- Market cap is approximately $12M; the authorized share count now exceeds market cap by orders of magnitude.
Financial Impact
Authorized shares increased from 75M to 1.5B — a 1,900% increase — enabling massive future dilution at a company with a ~$12M market cap.
Risk Factors
- Massive authorized share increase enables extreme dilution — potential for offerings that could reduce existing holders' stake to near-zero.
- No financial results or guidance provided in this filing — the share authorization without a disclosed use case increases uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001021771-26-000084 |
| Exhibit: ex99_1.htm | 0001021771-26-000084 |
| Document: brtx-20260529.htm | 0001021771-26-000084 |
| Document: 0001021771-26-000084-index-headers.html | 0001021771-26-000084 |
| Document: 0001021771-26-000084-index.html | 0001021771-26-000084 |
| Document: 0001021771-26-000084.txt | 0001021771-26-000084 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $1.75 | awaiting T+20 | — | $1.50 (−14.00%) |
Sep 11, 2026 6w ago | 8-K | $2.67 $1.91 | ▲ +28.46% | ▲ +30.33% | $1.50 (+43.63%) |
Sep 2, 2026 7w ago | Press Release | $0.1437 $2.14 | ▲ +1389.21% | ▲ +1389.67% | $1.50 (+947.32%) |
Aug 25, 2026 8w ago | 8-K | $0.2169 $2.51 | ▼ −1057.22% | ▼ −1057.07% | $1.50 (−593.87%) |
Jun 12, 2026 19w ago | 8-K | $0.3910 $0.3400 | ▲ +13.04% | ▲ +13.04% | $1.50 (−284.91%) |
May 29, 2026 21w ago | 8-K | $0.4064 $0.3760 | ▲ +7.48% | ▲ +6.18% | $1.50 (−270.32%) |
May 1, 2026 25w ago | 8-K | $0.2420 $0.4064 | ▲ +67.93% | ▲ +62.29% | $1.50 (+521.90%) |
Apr 7, 2026 29w ago | Press Release | $0.2507 $0.2420 | ▼ −3.47% | ▼ −13.25% | $1.50 (+500.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers